Do pentoxifylline and ascorbic acid improve erythropoiesis stimulating agent resistance?

Seminars in Dialysis

Volumn 24, Issue 4, 2011, Pages 378-379

  Rho, Mira ^a,b  

^a ST MARY S HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ASCORBIC ACID; PENTOXIFYLLINE;

ANEMIA; CHRONIC KIDNEY FAILURE; DRUG RESISTANCE; HUMAN; NOTE;

ANEMIA; ASCORBIC ACID; DRUG RESISTANCE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; PENTOXIFYLLINE;

EID: 80051815113     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00894.x     Document Type: Note

References (14)

1. Macdougall IC, et al.: The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 17(Suppl 1):48-52, 2002
2. Bridges KR, et al.: The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. J Biol Chem 261(30):14273-14277, 1986
3. Richter A, et al.: Vitamin C deficiency and secondary hyperparathyroidism in chronic haemodialysis patients. Nephrol Dial Transplant 23(6):2058-2063, 2008
4. Finkelstein FO, et al.: Hemoglobin and plasma vitamin C levels in patients on peritoneal dialysis. Perit Dial Int 31(1):74-79, 2011
5. Attallah N, et al.: Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 47(4):644-654, 2006
6. Sirover WD, et al.: Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study. Ren Fail 30(9):884-889, 2008
7. Deved V, et al.: Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis 54(6):1089-1097, 2009
8. Gastaldello K, et al.: Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 10(Suppl 6):44-47, 1995
9. Tarng DC, et al.: Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 55(6):2477-2486, 1999
10. Canavese C, et al.: Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis 45(3):540-549, 2005
11. Cooper AC, et al.: Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 14(7):1776-1784, 2003
12. Cooper A, et al.: Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 15(7):1877-1882, 2004
13. Navarro JF, et al.: Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand J Urol Nephrol 33(2):121-125, 1999
14. Johnson DW, et al.: Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrol 9:8, 2008